AKOYA BIOSCIENCES INC (AKYA)
US00974H1041 - Common Stock
Taking everything into account, AKYA scores 2 out of 10 in our fundamental rating. AKYA was compared to 55 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of AKYA have multiple concerns. AKYA is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year AKYA has reported negative net income.
In the past year AKYA has reported a negative cash flow from operations.
AKYA had negative earnings in each of the past 5 years.
In the past 5 years AKYA always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of AKYA (-44.60%) is worse than 87.27% of its industry peers.
AKYA has a Return On Equity of -425.20%. This is amonst the worse of the industry: AKYA underperforms 92.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -44.6% | ||
| ROE | -425.2% | ||
| ROIC | N/A |
ROA(3y)-32.83%
ROA(5y)-29.39%
ROE(3y)-91.62%
ROE(5y)-89.72%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 57.72%, AKYA is in the better half of the industry, outperforming 76.36% of the companies in the same industry.
AKYA's Gross Margin has declined in the last couple of years.
AKYA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 57.72% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.54%
GM growth 5YN/A
2. Health
2.1 Basic Checks
AKYA does not have a ROIC to compare to the WACC, probably because it is not profitable.
AKYA has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, AKYA has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -2.44, we must say that AKYA is in the distress zone and has some risk of bankruptcy.
AKYA has a worse Altman-Z score (-2.44) than 81.82% of its industry peers.
AKYA has a Debt/Equity ratio of 5.62. This is a high value indicating a heavy dependency on external financing.
AKYA's Debt to Equity ratio of 5.62 is on the low side compared to the rest of the industry. AKYA is outperformed by 92.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.62 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.44 |
ROIC/WACCN/A
WACC12.35%
2.3 Liquidity
A Current Ratio of 2.75 indicates that AKYA has no problem at all paying its short term obligations.
With a Current ratio value of 2.75, AKYA perfoms like the industry average, outperforming 45.45% of the companies in the same industry.
A Quick Ratio of 1.85 indicates that AKYA should not have too much problems paying its short term obligations.
AKYA has a Quick ratio of 1.85. This is comparable to the rest of the industry: AKYA outperforms 45.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.75 | ||
| Quick Ratio | 1.85 |
3. Growth
3.1 Past
AKYA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 32.75%, which is quite impressive.
Looking at the last year, AKYA shows a decrease in Revenue. The Revenue has decreased by -4.99% in the last year.
AKYA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 31.56% yearly.
EPS 1Y (TTM)32.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.77%
Revenue 1Y (TTM)-4.99%
Revenue growth 3Y31.56%
Revenue growth 5YN/A
Sales Q2Q%-25.13%
3.2 Future
Based on estimates for the next years, AKYA will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.27% on average per year.
AKYA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.25% yearly.
EPS Next Y27.07%
EPS Next 2Y26.9%
EPS Next 3Y20.84%
EPS Next 5Y13.27%
Revenue Next Year2.04%
Revenue Next 2Y9.81%
Revenue Next 3Y12.06%
Revenue Next 5Y12.25%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
AKYA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AKYA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
AKYA's earnings are expected to grow with 20.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.9%
EPS Next 3Y20.84%
5. Dividend
5.1 Amount
AKYA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AKOYA BIOSCIENCES INC
NASDAQ:AKYA (11/21/2024, 8:11:44 PM)
After market: 2.12 0 (0%)2.12
-0.04 (-1.85%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap105.07M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -44.6% | ||
| ROE | -425.2% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 57.72% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.67
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.62 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.75 | ||
| Quick Ratio | 1.85 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)32.75%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y27.07%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-4.99%
Revenue growth 3Y31.56%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y